Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and cardiac remodeling in heart failure with reduced ejection fraction

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and cardiac remodeling in heart failure with reduced ejection fraction - SAVASAVA Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048602

Enrollment

Registered

2022-08-05

Start date

2021-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with heart failure who finished the PARALLEL-HF trial

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with chronic HF in our hospital participated in the PARALLEL-HF trial

Exclusion criteria

Exclusion criteria: Patients who did not consent to participate

Design outcomes

Primary

Measure	Time frame
The primary endpoint was percent change (%Change) from baseline to week 24 in plasma A-, B-, and N-terminal pro-B-type natriuretic peptide (ANP, BNP, and NT-proBNP) levels.	—

Secondary

Measure	Time frame
The second endpoint was the change in echocardiographic parameters related to myocardial remodeling from the baseline to week 24.	—

Countries

Japan

Contacts

Public ContactAkihiro Nakamura

Iwate Prefectural Central Hospital Department of Cardiology

Akihironakamura0223@msn.com019-653-1151

Outcome results